During the past decade, Oncovida- Centro de Onco-Hematologia de Mato Grosso conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oncovida- Centro de Onco-Hematologia de Mato Grosso" #1 collaborator was "Incyte Corporation" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Oncovida- Centro de Onco-Hematologia de Mato Grosso" are "Systemic Lupus Erythematosus" (2 trials) and "Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol" (1 trials). Many other conditions were trialed in "Oncovida- Centro de Onco-Hematologia de Mato Grosso" in a lesser frequency.

Most popular intervention types in "Oncovida- Centro de Onco-Hematologia de Mato Grosso" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Baricitinib" (2 trials), "Placebo" (2 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oncovida- Centro de Onco-Hematologia de Mato Grosso" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Oncovida- Centro de Onco-Hematologia de Mato Grosso". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Oncovida- Centro de Onco-Hematologia de Mato Grosso, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Oncovida- Centro de Onco-Hematologia de Mato Grosso, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".